1. Home
  2. NTAP vs BIIB Comparison

NTAP vs BIIB Comparison

Compare NTAP & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NetApp Inc.

NTAP

NetApp Inc.

HOLD

Current Price

$165.63

Market Cap

30.3B

Sector

Technology

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$207.44

Market Cap

27.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTAP
BIIB
Founded
1992
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.3B
27.3B
IPO Year
1996
1996

Fundamental Metrics

Financial Performance
Metric
NTAP
BIIB
Price
$165.63
$207.44
Analyst Decision
Hold
Buy
Analyst Count
13
25
Target Price
$116.58
$206.83
AVG Volume (30 Days)
2.7M
1.1M
Earning Date
05-28-2026
04-29-2026
Dividend Yield
1.91%
N/A
EPS Growth
11.99
N/A
EPS
6.35
2.15
Revenue
$6,237,000,000.00
$9,890,600,000.00
Revenue This Year
$6.22
N/A
Revenue Next Year
$4.91
N/A
P/E Ratio
$25.78
$96.94
Revenue Growth
5.59
2.22
52 Week Low
$93.69
$121.06
52 Week High
$192.83
$219.72

Technical Indicators

Market Signals
Indicator
NTAP
BIIB
Relative Strength Index (RSI) 63.08 54.34
Support Level $95.25 $170.52
Resistance Level $192.83 $219.72
Average True Range (ATR) 6.46 6.91
MACD -0.95 0.42
Stochastic Oscillator 86.58 51.63

Price Performance

Historical Comparison
NTAP
BIIB

About NTAP NetApp Inc.

NetApp Inc is storage hardware provider into a software-driven, cloud-centric data infrastructure company. Its flagship ONTAP data management software, together with a comprehensive portfolio of all-flash, hybrid-flash, and cloud-native solutions, forms the backbone of digital transformation for thousands of enterprises world'wide. Its operations are organized into two segments Hybrid Cloud and Public Cloud. It generates majority of revenue from Hybrid Cloud offers a unified data storage portfolio of storage management and infrastructure solutions that helps customers modernize their data centers. Hybrid Cloud includes software, hardware, and related support, along with professional and other services. It generates majority of revenue from United States followed by International market.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: